Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Income from Continuing Operations: 2019-2024

Historic Income from Continuing Operations for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to -$56.6 million.

  • Compass Therapeutics' Income from Continuing Operations fell 29.23% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 41.55%. This contributed to the annual value of -$56.6 million for FY2024, which is 33.25% down from last year.
  • According to the latest figures from FY2024, Compass Therapeutics' Income from Continuing Operations is -$56.6 million, which was down 33.25% from -$42.5 million recorded in FY2023.
  • Over the past 5 years, Compass Therapeutics' Income from Continuing Operations peaked at -$37,483 during FY2020, and registered a low of -$82.2 million during FY2021.
  • Over the past 3 years, Compass Therapeutics' median Income from Continuing Operations value was -$42.5 million (recorded in 2023), while the average stood at -$46.1 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first tumbled by 178.58% in 2021, then surged by 52.27% in 2022.
  • Yearly analysis of 5 years shows Compass Therapeutics' Income from Continuing Operations stood at -$37,483 in 2020, then increased by 15.09% to -$29.5 million in 2020, then crashed by 178.58% to -$82.2 million in 2021, then spiked by 52.27% to -$39.2 million in 2022, then fell by 8.33% to -$42.5 million in 2023, then plummeted by 33.25% to -$56.6 million in 2024.